- Home
- App Analytics
- iTransfuse
- iTransfuse Vs. ARF RHD Guidelines
iTransfuse vs ARF RHD Guidelines Usage & Stats
The iTransfuse App promotes safe, appropriate and evidence-based transfusion by providing bedside access to transfusion education tools and resources. It includes information to support the prescription of red cells and platelets, diagnostic information about transfusion reactions, and much more.
- Apple App Store
- Free
- Medical
Store Rank
- -
Rheumatic heart disease represents the greatest cardiovascular inequality between Indigenous and non-Indigenous Australians. From 2013 to 2017, 94% of all new rheumatic heart disease cases were among Aboriginal and Torres Strait Islander people.
This app assists clinicians in the diagnosis and management of acute rheumatic fever and rheumatic heart disease. Published by RHDAustralia, based at Menzies School of Health Research, the app contains the most up-to-date evidence and details various aspects of patient care. It is informed by the 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition), available at https://www.rhdaustralia.org.au/arf-rhd-guideline. The app also contains an ARF Diagnosis Calculator which embeds the lengthy and complex ARF diagnosis algorithms into a series of simple questions that assist clinicians to diagnose ARF. The algorithms comply with the 2015 American Heart Association revision of the Jones Criteria for diagnosis of ARF, which has been endorsed by the World Heart Federation, making the Diagnosis Calculator now able to be used globally.
- Apple App Store
- Free
- Medical
Store Rank
- -
iTransfuse vs. ARF RHD Guidelines ranking comparison
Compare iTransfuse ranking trend in the past 28 days vs. ARF RHD Guidelines
Rank
No Data Available
iTransfuse vs. ARF RHD Guidelines ranking by country comparison
Compare iTransfuse ranking trend in the past 28 days vs. ARF RHD Guidelines
No Data to Display
Compare to any site with our free trial
iTransfuse VS.
ARF RHD Guidelines
December 14, 2024